Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Get Free Report) CEO Christopher Gibson sold 50,000 shares of the stock in a transaction that occurred on Wednesday, May 1st. The stock was sold at an average price of $7.73, for a total transaction of $386,500.00. Following the transaction, the chief executive officer now directly owns 863,524 shares of the company's stock, valued at approximately $6,675,040.52. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.
Christopher Gibson also recently made the following trade(s):
- On Wednesday, April 3rd, Christopher Gibson sold 40,000 shares of Recursion Pharmaceuticals stock. The stock was sold at an average price of $8.84, for a total value of $353,600.00.
- On Thursday, March 28th, Christopher Gibson sold 40,000 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $10.10, for a total value of $404,000.00.
- On Wednesday, March 6th, Christopher Gibson sold 36,319 shares of Recursion Pharmaceuticals stock. The stock was sold at an average price of $11.86, for a total value of $430,743.34.
- On Wednesday, February 7th, Christopher Gibson sold 48,272 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $9.22, for a total value of $445,067.84.
Recursion Pharmaceuticals Trading Up 0.6 %
Protect Your Bank Account Before It’s Too Late
From Weiss Ratings | Ad
For months I’ve been warning about the federal government’s terrifying new program to control every American’s bank account.
It gives them the power to monitor every single transaction …
Stop right now and do these 3 things to protect yourself
Shares of RXRX opened at $8.84 on Friday. Recursion Pharmaceuticals, Inc. has a 1 year low of $4.80 and a 1 year high of $16.75. The stock has a 50-day simple moving average of $9.97 and a 200-day simple moving average of $9.16.
Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last issued its quarterly earnings results on Tuesday, February 27th. The company reported ($0.40) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.46) by $0.06. Recursion Pharmaceuticals had a negative net margin of 735.99% and a negative return on equity of 72.88%. The company had revenue of $10.89 million during the quarter, compared to the consensus estimate of $12.37 million. As a group, equities analysts predict that Recursion Pharmaceuticals, Inc. will post -1.63 earnings per share for the current year.
Analyst Ratings Changes
Several research analysts have recently commented on the stock. Needham & Company LLC reissued a "buy" rating and issued a $17.00 price objective on shares of Recursion Pharmaceuticals in a research note on Tuesday, April 9th. KeyCorp increased their target price on shares of Recursion Pharmaceuticals from $15.00 to $16.00 and gave the stock an "overweight" rating in a report on Monday, March 4th. Finally, TD Cowen began coverage on shares of Recursion Pharmaceuticals in a research note on Friday, January 26th. They issued a "market perform" rating for the company. Three research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus price target of $12.75.
Check Out Our Latest Research Report on RXRX
Hedge Funds Weigh In On Recursion Pharmaceuticals
A number of institutional investors and hedge funds have recently modified their holdings of the company. SG Americas Securities LLC lifted its holdings in Recursion Pharmaceuticals by 21.2% during the 3rd quarter. SG Americas Securities LLC now owns 38,927 shares of the company's stock worth $298,000 after buying an additional 6,818 shares during the last quarter. Commonwealth Equity Services LLC lifted its stake in Recursion Pharmaceuticals by 35.5% during the third quarter. Commonwealth Equity Services LLC now owns 21,185 shares of the company's stock worth $162,000 after purchasing an additional 5,550 shares during the last quarter. Cambridge Investment Research Advisors Inc. acquired a new position in Recursion Pharmaceuticals in the third quarter valued at approximately $458,000. Raymond James & Associates purchased a new position in Recursion Pharmaceuticals in the third quarter valued at approximately $529,000. Finally, Independent Advisor Alliance acquired a new stake in Recursion Pharmaceuticals during the third quarter worth approximately $96,000. Institutional investors and hedge funds own 89.06% of the company's stock.
Recursion Pharmaceuticals Company Profile
(
Get Free Report)
Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
